Flagship adds asset-centric strategy to get more from its platform technologies

Flagship Pioneering, whose investment strategy has always been blue-sky platform plays or bust, has decided to embrace single-assets. The change is more of an evolution than a revolution though, as the idea is to draw from its own portfolio companies, helping them advance more programs than they could alone.

Flagship's new executive partner Paul Biondi will head the Pioneering Medicines unit, an internal drug development group created to house promising but deprioritized assets from Flagship's platform companies within separate LLCs. Biondi joined in December; he was previously SVP of strategy and business development at Bristol-Myers Squibb Co. (NYSE:BMY)...